IGC Pharma reports positive interim Phase 2 results for IGC-AD1 in Alzheimer's agitation

IGC Pharma, Inc.

Cohen's d effect size at week 6=0.66, CMAI LS mean difference vs placebo=-10.45, p=0.037.
At pre-specified week 2 endpoint, effect size=0.79, suggesting early onset of action.
Interim results compare favorably to Brexpiprazole's Phase 3 (Cohen's d 0.35, LS mean -5.32).
Trial ongoing (n=26 interim); final results may differ as enrollment continues in US and Canada.
IGC-AD1 targets CB1 receptor, neuroinflammation, and inflammasome-3 pathways.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.